TBPH FY 2017 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-68.4% YoY

Gross Profit

$9M60.8% margin

Operating Income

-$260M-1690.6% margin

Net Income

-$285M-1855.0% margin

EPS (Diluted)

$-5.45

Cash Flow

Operating Cash Flow

-$201M

Free Cash Flow

-$203M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$441M

Total Liabilities

$326M

Stockholders' Equity

$115M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$49M	-68.4%
Gross Profit	$9M	$46M	-79.6%
Operating Income	-$260M	-$180M	-44.1%
Net Income	-$285M	-$191M	-49.7%